Innovent Biologics (OTCMKTS:IVBXF) Shares Down 6.2%

Shares of Innovent Biologics, Inc. (OTCMKTS:IVBXFGet Free Report) fell 6.2% on Tuesday . The stock traded as low as $3.83 and last traded at $3.83. 5,578 shares changed hands during trading, a decline of 99% from the average session volume of 658,528 shares. The stock had previously closed at $4.09.

Innovent Biologics Stock Performance

The firm has a 50 day moving average of $4.99 and a 200 day moving average of $4.84.

Innovent Biologics Company Profile

(Get Free Report)

Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.

See Also

Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with's FREE daily email newsletter.